Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, and Karolinska University Hospital, Sweden.
Department of Public Health, University of Copenhagen, Denmark.
Ann Surg. 2023 Dec 1;278(6):904-909. doi: 10.1097/SLA.0000000000006003. Epub 2023 Jul 14.
OBJECTIVE: The objective of this study was to test the hypothesis that bariatric surgery decreases the risk of esophageal and cardia adenocarcinoma. BACKGROUND: Obesity is strongly associated with esophageal adenocarcinoma and moderately with cardia adenocarcinoma, but whether weight loss prevents these tumors is unknown. METHODS: This population-based cohort study included patients with an obesity diagnosis in Sweden, Finland, or Denmark. Participants were divided into a bariatric surgery group and a nonoperated group. The incidence of esophageal and cardia adenocarcinoma (ECA) was first compared with the corresponding background population by calculating standardized incidence ratios (SIR) with 95% CIs. Second, the bariatric surgery group and the nonoperated group were compared using multivariable Cox regression, providing hazard ratios (HR) with 95% CI, adjusted for sex, age, comorbidity, calendar year, and country. RESULTS: Among 748,932 participants with an obesity diagnosis, 91,731 underwent bariatric surgery, predominantly gastric bypass (n=70,176; 76.5%). The SIRs of ECA decreased over time after gastric bypass, from SIR=2.2 (95% CI, 0.9-4.3) after 2 to 5 years to SIR=0.6 (95% CI, <0.1-3.6) after 10 to 40 years. Gastric bypass patients were also at a decreased risk of ECA compared with nonoperated patients with obesity [adjusted HR=0.6, 95% CI, 0.4-1.0 (0.98)], with decreasing point estimates over time. Gastric bypass was followed by a strongly decreased adjusted risk of esophageal adenocarcinoma (HR=0.3, 95% CI, 0.1-0.8) but not of cardia adenocarcinoma (HR=0.9, 95% CI, 0.5-1.6), when analyzed separately. There were no consistent associations between other bariatric procedures (mainly gastroplasty, gastric banding, sleeve gastrectomy, and biliopancreatic diversion) and ECA. CONCLUSIONS: Gastric bypass surgery may counteract the development of esophageal adenocarcinoma in morbidly obese individuals.
目的:本研究旨在验证假设,即减重手术可降低食管腺癌和贲门腺癌的发病风险。
背景:肥胖与食管腺癌高度相关,与贲门腺癌中度相关,但减重是否可预防这些肿瘤尚不清楚。
方法:本基于人群的队列研究纳入了在瑞典、芬兰或丹麦被诊断为肥胖的患者。参与者分为减重手术组和未手术组。首先通过计算标准化发病比(SIR)及其 95%置信区间(CI),将食管腺癌和贲门腺癌(ECA)的发病率与相应的基础人群进行比较。其次,通过多变量 Cox 回归比较减重手术组和未手术组,提供调整性别、年龄、合并症、日历年份和国家后的风险比(HR)及其 95%CI。
结果:在 748932 名被诊断为肥胖的参与者中,91731 名接受了减重手术,主要为胃旁路手术(n=70176;76.5%)。胃旁路手术后 ECA 的 SIR 随时间逐渐降低,从 2 至 5 年的 SIR=2.2(95%CI,0.9-4.3)降至 10 至 40 年的 SIR=0.6(95%CI,<0.1-3.6)。与肥胖未手术患者相比,胃旁路手术患者 ECA 的发病风险也降低[校正 HR=0.6,95%CI,0.4-1.0(0.98)],且时间依赖性点估计值逐渐降低。胃旁路手术后食管腺癌的调整风险显著降低(HR=0.3,95%CI,0.1-0.8),而贲门腺癌的调整风险无显著降低(HR=0.9,95%CI,0.5-1.6),当分别分析时。其他减重手术(主要为胃成形术、胃束带术、胃袖状切除术和胆胰分流术)与 ECA 之间无一致关联。
结论:胃旁路手术可能可逆转肥胖个体食管腺癌的发展。
JAMA Surg. 2023-3-1
Cochrane Database Syst Rev. 2014-8-8
Surg Obes Relat Dis. 2017-1
Arq Bras Cir Dig. 2024-12-2